Background: Dapagliflozin, sodium glucose cotransporter 2 inhibitor, has potential side
effects on electrolyte imbalance as it has diuretic effects which include decreasing glucose reabsorption,
increasing glucosuria and natriuresis. We aimed to determine the possible effects of dapagliflozin
on electrocardiogram (ECG) in patients with type 2 DM.
Material and Methods: This retrospective study consisted of 49 patients (25 female, 24 male). Patients
who had inadequate glycemic control besides using several oral antidiabetics, subsequently endorsed
with dapagliflozin, were included in the current study.
Results: Meantime interval from treatment initiation to control was 10.5 ± 5.03 weeks. Body mass
index, glucose, HbA1C, eGFR, LDL-C, heart rate, systolic and diastolic blood pressures were found to
be significantly lower at control admission (p<0.05). Creatinine and QT interval were significantly
higher at control admission (p<0.05). Baseline Tpe duration and baseline Tpe/QT ratio were found to
be significantly correlated with Tpe/QT difference (p<0.05). In linear regression analysis, baseline
Tpe/QT ratio was found to be the sole independent predictor of Tpe/QT difference (p<0.05).
Conclusion: Initiation of dapagliflozin treatment seems to be safe, up to several months, in terms of
serum electrolytes and ECG findings in patients with type 2 DM with a probable improvement.